Patritumab Deruxtecan
Phase 1/2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Trial Timeline
Nov 28, 2016 → Sep 7, 2023
NCT ID
NCT02980341About Patritumab Deruxtecan
Patritumab Deruxtecan is a phase 1/2 stage product being developed by Daiichi Sankyo for Metastatic Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02980341. Target conditions include Metastatic Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Breast Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05620914 | Phase 2 | Withdrawn |
| NCT06941272 | Phase 1/2 | Recruiting |
| NCT06596694 | Phase 1/2 | Recruiting |
| NCT05865990 | Phase 2 | Active |
| NCT04479436 | Phase 2 | Terminated |
| NCT02980341 | Phase 1/2 | Completed |
Competing Products
20 competing products in Metastatic Breast Cancer